The Effects of Rituximab on Lipids, Arterial Stiffness and Carotid Intima-Media Thickness in Rheumatoid Arthritis
- PMID: 26839473
- PMCID: PMC4729499
- DOI: 10.3346/jkms.2016.31.2.202
The Effects of Rituximab on Lipids, Arterial Stiffness and Carotid Intima-Media Thickness in Rheumatoid Arthritis
Abstract
The aim of the study was to examine lipid profiles, arterial stiffness (AS), carotid intima-media thickness (cIMT), in 55 women with RA without overt cardiovascular disease (СVD) treated with rituximab (RTX).The following parameters were recorded before and 24 weeks after RTX therapy (2 infusions of 500 or 1,000 mg RTX intravenously, fortnightly): plasma total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides, DAS 28-ESR, serum C-reactive protein (CRP), RF IgM, AS (SI - stiffness index, RI - reflection index) by digital volume pulse contour analysis (Micro Medical, UK), and common cIMT by high-resolution B-mode carotid ultrasound. Based on the European League Against Rheumatism (EULAR) criteria, patients were divided into two groups: 1) moderate/good response to RTX therapy after 24 weeks (41 patients, 75%), 2) no response to RTX therapy (14 patients, 25%). Effective RTX therapy resulted in 9% increase in TC, 23% increase in HDL-C and 14% decrease in atherogenic index, 57% decrease in SI and 24% decrease in RI. We observed a 9% decrease of cIMTmax at 24 weeks. The improvement of cardiovascular parameters was accompanied by statistically significant decreases of CRP, ESR, RF IgM and DAS 28 in group 1 (P < 0.05). There were not significant changes in lipid profile, AS parameters, and cIMT in group 2. Two infusions of RTX in case of moderate/good EULAR effect of therapy exerted favorable effects on lipid profile, AS and cIMT in women with RA without overt CVD.
Keywords: Arterial Stiffness; Carotid Atherosclerosis; Lipids; Rheumatoid Arthritis; Rituximab.
Conflict of interest statement
Similar articles
-
Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis.Clin Rheumatol. 2009 Jun;28(6):705-10. doi: 10.1007/s10067-009-1095-1. Epub 2009 Mar 25. Clin Rheumatol. 2009. PMID: 19319624 Clinical Trial.
-
HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab.Ann Rheum Dis. 2013 Apr;72(4):560-5. doi: 10.1136/annrheumdis-2011-201228. Epub 2012 May 15. Ann Rheum Dis. 2013. PMID: 22589377 Clinical Trial.
-
[Association between systemic inflammation and autoimmunity parameters and plasma lipid in patients with rheumatoid arthritis].Zhonghua Xin Xue Guan Bing Za Zhi. 2011 Oct;39(10):941-5. Zhonghua Xin Xue Guan Bing Za Zhi. 2011. PMID: 22321280 Chinese.
-
Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis.Vascul Pharmacol. 2016 Jun;81:22-30. doi: 10.1016/j.vph.2016.01.006. Epub 2016 Feb 21. Vascul Pharmacol. 2016. PMID: 26903239 Review.
-
Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience.Clin Exp Rheumatol. 2009 May-Jun;27(3):446-51. Clin Exp Rheumatol. 2009. PMID: 19604437 Review.
Cited by
-
Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion.J Cell Mol Med. 2019 Sep;23(9):6308-6318. doi: 10.1111/jcmm.14517. Epub 2019 Jul 26. J Cell Mol Med. 2019. PMID: 31347786 Free PMC article.
-
Cardiovascular Risk Assessment in Rheumatoid Arthritis: Accelerated Atherosclerosis, New Biomarkers, and the Effects of Biological Therapy.Life (Basel). 2023 Jan 23;13(2):319. doi: 10.3390/life13020319. Life (Basel). 2023. PMID: 36836675 Free PMC article. Review.
-
Inflammaging as a link between autoimmunity and cardiovascular disease: the case of rheumatoid arthritis.RMD Open. 2021 Jan;7(1):e001470. doi: 10.1136/rmdopen-2020-001470. RMD Open. 2021. PMID: 33468563 Free PMC article. Review.
-
Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis.RMD Open. 2019 Jul 21;5(2):e000897. doi: 10.1136/rmdopen-2019-000897. eCollection 2019. RMD Open. 2019. PMID: 31413865 Free PMC article. Clinical Trial.
-
Haematological Drugs Affecting Lipid Metabolism and Vascular Health.Biomedicines. 2022 Aug 10;10(8):1935. doi: 10.3390/biomedicines10081935. Biomedicines. 2022. PMID: 36009482 Free PMC article. Review.
References
-
- Mellana WM, Aronow WS, Palaniswamy C, Khera S. Rheumatoid arthritis: cardiovascular manifestations, pathogenesis, and therapy. Curr Pharm Des. 2012;18:1450–1456. - PubMed
-
- Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59:1690–1697. - PubMed
-
- Kerekes G, Szekanecz Z, Dér H, Sándor Z, Lakos G, Muszbek L, Csipö I, Sipka S, Seres I, Paragh G, et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol. 2008;35:398–406. - PubMed
-
- Ambrosino P, Tasso M, Lupoli R, Di Minno A, Baldassarre D, Tremoli E, Di Minno MN. Non-invasive assessment of arterial stiffness in patients with rheumatoid arthritis: a systematic review and meta-analysis of literature studies. Ann Med. 2015;47:457–467. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous